• S. Maliborska Ivano-Frankivsk National Medical University, Department of Oncology, Ivano-Frankivsk, Ukraine
  • V. Holotiuk Ivano-Frankivsk National Medical University, Department of Oncology, Ivano-Frankivsk, Ukraine
  • Y. Partykevych Prykarpatsky Clinical Oncology Center of the Ivano-Frankivsk Regional Council”, Ivano-Frankivsk, Ukraine
  • O. Rossylna Clinic for Personalized Diagnostics and Therapy Design “Oncotheranostics”, Kyiv, Ukraine



colorectal cancer, microRNA, prognosis, metastases


Background. The discovery of new markers for colorectal cancer (CRC) is of paramount importance for improving the diagnosis, prognosis, and treatment of this disease. CRC is the third most common cancer worldwide and the second leading cause of cancer-related deaths. Early detection and treatment are crucial for improving patient outcomes, but current screening methods are not foolproof. Additionally, there is a need for better prognostic markers to identify patients at high risk of recurrence or metastasis, who may benefit from more aggressive treatment. Objectives: To analyze the expression profile of miR-100, miR-125b, and miR-200b in the blood serum of CRC patients and assess its correlation with the clinicopathological factors of cancer course. Materials and Methods. Twenty blood serum samples from CRC patients were analyzed by the real-time polymerase chain reaction for miR-100, miR-125b, and miR-200b expressions. The results were normalized and then analyzed using statistical tests. Results. According to our results, miR-125b and -200b expressions correlate with T (r = –0.51 and 0.6, respectively, p < 0.05) and N (r = 0.47 and –0.52, respectively, p < 0.05). Also, miR-125b levels were 1.56 times higher and mir- 200b – 1.59 times lower in patients with metastases in the regional lymph nodes. Conclusions. Observed levels of miR-125b and -200b in correlation with tumor stage and lymph node metastasis among CRC patients demonstrate their potential clinical utility as minimally invasive biomarkers for the prognosis of cancer course. Therefore, further validation studies with larger participant cohorts are necessary.


Siegel RL, Miller KD, Goding SA, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164.

Montminy EM, Zhou M, Maniscalco L, et al. Contributions of adenocarcinoma and carcinoid tumors to early-onset colorectal cancer incidence rates in the United States. Ann Intern Med. 2021;174(2):157-166.

Li N, Lu B, Luo C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255-268.

Jung G, Hernández-Illán E, Moreira L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-130.

Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep. 2022;10:goac035.

Wai Hon K, Zainal Abidin SA, Othman I, Naidu R. Insights into the role of microRNAs in colorectal cancer (CRC) metabolism. Cancers. 2020;12:2462.

Ghafouri-Fard S, Hussen BM, Badrlou E, et al. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. Biomed. Pharmacother. 2021;140:111759.

Pastor-Navarro B, García-Flores M, Fernández-Serra A, et al. A tetra-panel of serum circulating mirnas for the diagnosis of the four most prevalent tumor types. Int J Mol Sci. 2020;21:2783.

Zanutto S, Ciniselli CM, Belfiore A, et al. Plasma miRNA-based signatures in CRC screening programs. Int J Cancer. 2020;146(4):1164-1173.

Ahadi A. The significance of microRNA deregulation in colorectal cancer development and the clinical uses as a diagnostic and prognostic biomarker and therapeutic agent. Non-coding RNA Res. 2020;5:125-134.

Li R, Qu H, Wang S, et al. CancerMIRNome: an interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Res. 2022;50(D1):D1139-D1146.

Unified clinical protocol of medical care (UCPMD) Colorectal cancer, 2016, Ministry of Health of Ukraine (in Ukrainian).

Buchynska LG, Borikun TV, Iurchenko NP, et al. Expression of microRNA in tumor cells of endmetrioid carcinoma of endometrium. Exp Oncol. 2020;42:289-294. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15522

Ye J, Xu M, Tian X, et al. Research advances in the detection of miRNA. J Pharm Anal. 2019;9:217-226.

Chen P, Xi Q, Wang Q, Wei P. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer. Med Oncol. 2014;31:1-6.

Cha DJ, Franklin JL, Dou Y, et al. KRAS-dependent sorting of miRNA to exosomes. Elife. 2015;4:e07197.

Yang XD, Xu XH, Zhang SY, et al. Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res. 2015;5:545.

Yamada A, Horimatsu T, Okugawa Y, et al. Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015;21:4234-4242.

Zhu SH, He XC, Wang L. Correlation analysis of miR-200b, miR-200c, and miR-141 with liver metastases in colorectal cancer patients. Eur Rev Med Pharmacol Sci. 2017;21:2357-2363.

Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259:735.




How to Cite

Maliborska, S., Holotiuk, V., Partykevych, Y., & Rossylna, O. (2024). PROGNOSTIC SIGNIFICANCE OF microRNA-100, -125b, AND -200b IN PATIENTS WITH COLORECTAL CANCER. Experimental Oncology, 45(4), 443–450.



Original contributions